Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vir Biotechnology, Inc.

NASDAQ: VIR · Life Sciences · 9 alerts · CIK 1706431

Vir Biotechnology, Inc. stories on ALFA USA NewsRead the news →
Share price
$9.58Close, Nov 16
Market cap
$1.64B
Shares outstanding
171.27MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vir Biotechnology, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Capital Raise

Vir Biotechnology Capital Raise of $150M

Vir Biotechnology entered into an underwriting agreement to sell 15,000,000 shares of common stock at a public offering price of $10.00 per share. The company expects to receive approximately $140.4 million in net proceeds, or $161.5 million if the underwriters exercise their 30-day option to purchase an additional 2,250,000 shares.

Value
$150M
Counterparty
Leerink Partners LLC
8:31 AM ET 8-K
Clinical Trial Data

Vir Biotechnology Clinical Trial Data

Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.

8:35 AM ET 8-K
Research Collaboration

Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B

Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.

Value
$1.88B
Counterparty
Gilead Sciences, Inc.
8:39 AM ET 8-K
Regulatory Approval

Vir Biotechnology Regulatory Approval

Vir Biotechnology announced that the FDA has granted Fast Track designation to VIR-5500, a PSMA-targeted T-cell engager being co-developed with Astellas Pharma for the treatment of metastatic castration-resistant prostate cancer. The designation is intended to expedite the development and review of the drug, which is currently in Phase 1 trials with Phase 3 development anticipated to begin in 2027.

Counterparty
Astellas Pharma Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.